GSK · Pharma and healthcare · one day
GSK (GSK): news on Thursday 22 October 2026
News from the 24 hours to Thursday morning, 22 October 2026.
Tone of the day
+10.0strongly positive
+10.0
Relevant headlines37
Stories9
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
What drove it
- Hibsago FDA approval
- ViiV CEO departure to CSL
- analyst ratings
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Fri 16 Oct | +0.8 | 16 |
| Sat 17 Oct | +2.0 | 10 |
| Sun 18 Oct | +0.7 | 2 |
| Mon 19 Oct | +8.5 | 7 |
| Tue 20 Oct | +8.3 | 37 |
| Wed 21 Oct | +10.0 | 26 |
| Thu 22 Oct | +10.0 | 37 |
| Fri 23 Oct | +7.2 | 18 |
| Sat 24 Oct | +8.0 | 15 |
| Sun 25 Oct | +2.0 | 6 |
| Mon 26 Oct | +5.7 | 5 |
9 stories · 37 headlines · strongest first
Pharma and healthcare on 22 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| FDA clears Hibsago, GSK's medicine for chronic hepatitis B +10.023 headlines today · 45 in all, since 21 October · Many outlets report FDA approval of Hibsago (bepirovirsen), with analyst and commentary pieces. | ||
| +10.0 | US approval of Hibsago for chronic hepatitis B. | |
| +10.0 | FDA approval of potential functional cure. | |
| +10.0 | Approved as first functional cure. | |
| +10.0 | The first medicine of its type for hepatitis B receives approval. | |
| +10.0 | FDA nod for functional cure. | |
| +10.0 | Functional cure receives approval in the US. | |
| +10.0 | First antisense treatment approved for hepatitis B. | |
| +10.0 | First ASO approved in chronic hepatitis B. | |
| +10.0 | FDA approval for chronic hepatitis B. | |
| +10.0 | Hibsago is approved by the FDA. | |
| +10.0 | FDA approval of hepatitis B drug. | |
| +10.0 | Bepirovirsen injection gets the FDA's approval. | |
| +10.0 | FDA approval offering patients treatment options. | |
| +10.0 | FDA clears first ASO for hepatitis B. | |
| +10.0 | Hep B drug approval won. | |
| +10.0 | GSK lands FDA first, among other stories. | |
| +10.0 | Approval supports sales forecast per Jefferies. | |
| +10.0 | Shares in focus on US approval. | |
| +10.0 | Approval draws attention to its strategy for a functional cure. | |
| +10.0 | Ionis partner announces approval; GSK named party. | |
| +6.7 | Approval mentioned from a manufacturing angle. | |
| +5.0 | Approval coverage with caveats in the fine print. | |
| −4.2 | Next-generation hep B trial scrapped. | |
| GSK's Deborah Waterhouse picked to lead CSL as chief executive −3.35 headlines today · 6 in all · CSL named ViiV CEO Deborah Waterhouse as its next CEO. | ||
| −5.0 | ViiV CEO departing to rival CSL; leadership loss. | |
| −5.0 | ViiV CEO leaves for CSL after three decades. | |
| −4.2 | Senior GSK executive poached by CSL. | |
| −4.2 | GSK executive named CSL CEO. | |
| −3.3 | CSL appoints GSK's Waterhouse; leadership departure. | |
| Brokers rate GSK +0.82 headlines today · JP Morgan keeps Sell and Jefferies Buy at 2,500p. | ||
| +8.3 | Jefferies reiterates Buy rating. | |
| −6.7 | JP Morgan keeps Sell rating. | |
| GSK share price and valuation commentary +3.22 headlines today · 27 in all, since 16 October · Breakingviews commentary and pre-market share price. | ||
| +7.5 | Commentary positive on pipeline progress, still needs more. | |
| +0.8 | Share price quote, factual pre-market update. | |
| GSK to invest over $800m in Pennsylvania +7.81 headline today · 23 in all, since 10 October · Patch examines GSK's $800 million growth plan in King of Prussia. | ||
| +8.3 | $800 million US expansion investment. | |
| GSK severe asthma medicine article +7.51 headline today · MediaPost covers GSK's new severe asthma medicine. | ||
| +7.5 | New severe asthma medicine reduces attacks. | |
| ViiV Cabenuva real-world evidence +7.51 headline today · Five years of real-world evidence reinforce Cabenuva's effectiveness. | ||
| +7.5 | Real-world evidence supports ViiV's Cabenuva. | |
| GSK Mubadala Bio partnership in UAE +6.71 headline today · Mubadala Bio's IDS and GSK signed a partnership for GSK medicines in the UAE. | ||
| +6.7 | Partnership expands access to GSK medicines in UAE. | |
| GSK earnings preview −4.21 headline today · Analysts estimate a decline in earnings. | ||
| −4.2 | Analysts expect earnings decline. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated GSK: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.